These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34405958)

  • 21. The safety of infliximab infusions in the community setting.
    Ducharme J; Pelletier C; Zacharias R
    Can J Gastroenterol; 2010 May; 24(5):307-11. PubMed ID: 20485705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of infliximab in children with IBD: the experience of an academic center in WV.
    Northcutt M; Al-Subu A; Bella B; Elitsur Y
    W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
    Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
    Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
    van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of rapid infliximab infusions on access at a large academic tertiary medical center.
    Pusateri A; Hatcher A; Patel N; Lehman J; Hinton A; Afzali A
    Am J Health Syst Pharm; 2021 Nov; 78(22):2046-2052. PubMed ID: 34050749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
    Ma D; Wong W; Aviado J; Rodriguez C; Wu H
    Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
    Lee TW; Singh R; Fedorak RN
    Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
    Little RD; Ward MG; Sparrow MP
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2430-2431. PubMed ID: 36155249
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
    Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.
    Dubinsky MC; Mendiolaza ML; Phan BL; Moran HR; Tse SS; Mould DR
    Inflamm Bowel Dis; 2022 Sep; 28(9):1375-1385. PubMed ID: 34978325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
    Baert F; Drobne D; Gils A; Vande Casteele N; Hauenstein S; Singh S; Lockton S; Rutgeerts P; Vermeire S
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1474-81.e2; quiz e91. PubMed ID: 24486408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.